12:32 PM EST, 11/03/2025 (MT Newswires) -- Revolution Medicines ( RVMD ) is positioned to execute targeting rat sarcoma-mutated tumor cancers, given its "impressive" efficacy data and focused pipeline, RBC Capital Markets said in a Monday research report.

Channel checks indicate daraxonrasib's benefits in treating solid tumors with specific RAS mutations could be reproduced in phase 3 trials with a readout expected in 2026. The company's comprehensive RAS, on-approach could drive better inhibition of the target, according to the note.

The brokerage said there is a desire to prescribe the drug to all pancreatic ductal adenocarcinoma patients. The analysts said they see a total opportunity of about $7.5 billion.

The regulatory path for daraxonrasib is also significantly derisked after the recent grant of the Commissioner's National Priority Voucher from the US Food and Drug Administration, RBC stated.

The brokerage initiated coverage of the stock with an outperform, speculative risk rating and a price target of $77 per share.

Price: 57.54, Change: -1.30, Percent Change: -2.21